Reports Q2 revenue $4.853M, consensus $1.6M. “The introduction today of Voyager’s vectorized anti-Abeta gene therapy research initiative expands our Alzheimer’s disease portfolio, complementing our anti-tau antibody and tau knock-down gene therapy programs,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. “We are encouraged by recent approvals in Alzheimer’s disease, and we believe this establishes a path forward for new approaches to existing targets, as well as new targets, to help address the heterogeneity of the massive Alzheimer’s disease population. Our anti-tau antibody VY-TAU01 remains on track for IND in the first half of 2024, and we continue to advance our growing pipeline of wholly-owned and partnered CNS gene therapies leveraging our neurotropic TRACER capsids.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VYGR:
- Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results
- Voyager Therapeutics to Present at the Canaccord Genuity Growth Conference
- Voyager Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
- Voyager Therapeutics participates in a conference call hosted by Truist
- Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)